ArticleFrontiers in endocrinology2026
Repurposing a prostate tumor marker: elevated FPSA/TPSA ratio as a novel non-invasive biomarker for declining eGFR in male type 2 diabetes.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic kidney disease (DKD) lacks accessible, cost-effective biomarkers for early screening. Given the distinct clearance pathways of free prostate-specific antigen (FPSA, renally excreted) and total prostate-specific antigen (TPSA, hepatically metabolized), this study investigated the association between serum FPSA/TPSA ratio and estimated glomerular filtration rate (eGFR) in male patients with type 2 diabetes mellitus (T2DM). Methods: In this real-world cross-sectional study, 4,487 male patients with T2DM were retrospectively enrolled. eGFR was determined using the Kidney Disease: Improving Global Outcomes (KDIGO)-recommended Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine-cystatin C (Cr-CysC) equation. Multivariable linear regression and subgroup analyses were conducted to elucidate the independent effect of the FPSA/TPSA ratio on eGFR, with adjustment for age, prostate-specific diseases, and metabolic confounders. Results: Baseline TPSA levels remained stable across renal function stages (median 0.9ng/ml, P = 0.524), minimizing interference from macroscopic prostate pathologies. After adjustment for age and metabolic profiles, the FPSA/TPSA ratio exhibited a robust independent negative association with eGFR (β = -0.2, P < 0.001). This inverse correlation remained consistent across all clinical subgroups (P for interaction > 0.05), with a more pronounced predictive trend among elderly patients (≥ 65 years). Notably, our multivariable models also captured the chronic kidney disease "lipid paradox", whereby higher triglyceride levels paradoxically correlated with preserved eGFR (β = 0.51, P = 0.018). Conclusion: An elevated serum FPSA/TPSA ratio is a robust, non-invasive indicator of declining eGFR in male patients with T2DM and may improve DKD risk stratification and early clinical warning without additional economic burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.